About Angiomotin
Angiomotin (AMOT) is a protein
from Homo sapiens identified by UniProt accession
Q4VCS5, 1084 residues long.
MolForge cross-references it against 0 known binders and
67 disease associations.
Target properties
| Protein name | Angiomotin |
|---|
| UniProt accession | Q4VCS5 |
|---|
| Gene | AMOT |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1084 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (67)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.53
- Rare genetic intellectual disability with developmental anomaly · score 0.27
- renal cell carcinoma · score 0.07
- neoplasm · score 0.07
- non-alcoholic fatty liver disease · score 0.04
- obstructive sleep apnea · score 0.04
- atrial fibrillation · score 0.03
- cholangiocarcinoma · score 0.03
- hematocrit · score 0.02
- erythrocyte count · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q4VCS5-F1 | alphafold | PREDICTED | 56.76 | — |
Amino-acid sequence (1084 residues)
MRNSEEQPSG GTTVLQRLLQ EQLRYGNPSE NRSLLAIHQQ ATGNGPPFPS GSGNPGPQSD VLSPQDHHQQ LVAHAARQEP QGQEIQSENL IMEKQLSPRM QNNEELPTYE EAKVQSQYFR GQQHASVGAA FYVTGVTNQK MRTEGRPSVQ RLNPGKMHQD EGLRDLKQGH VRSLSERLMQ MSLATSGVKA HPPVTSAPLS PPQPNDLYKN PTSSSEFYKA QGPLPNQHSL KGMEHRGPPP EYPFKGMPPQ SVVCKPQEPG HFYSEHRLNQ PGRTEGQLMR YQHPPEYGAA RPAQDISLPL SARNSQPHSP TSSLTSGGSL PLLQSPPSTR LSPARHPLVP NQGDHSAHLP RPQQHFLPNQ AHQGDHYRLS QPGLSQQQQQ QQQQHHHHHH HQQQQQQQPQ QQPGEAYSAM PRAQPSSASY QPVPADPFAI VSRAQQMVEI LSDENRNLRQ ELEGCYEKVA RLQKVETEIQ RVSEAYENLV KSSSKREALE KAMRNKLEGE IRRMHDFNRD LRERLETANK QLAEKEYEGS EDTRKTISQL FAKNKESQRE KEKLEAELAT ARSTNEDQRR HIEIRDQALS NAQAKVVKLE EELKKKQVYV DKVEKMQQAL VQLQAACEKR EQLEHRLRTR LERELESLRI QQRQGNCQPT NVSEYNAAAL MELLREKEER ILALEADMTK WEQKYLEENV MRHFALDAAA TVAAQRDTTV ISHSPNTSYD TALEARIQKE EEEILMANKR CLDMEGRIKT LHAQIIEKDA MIKVLQQRSR KEPSKTEQLS CMRPAKSLMS ISNAGSGLLS HSSTLTGSPI MEEKRDDKSW KGSLGILLGG DYRAEYVPST PSPVPPSTPL LSAHSKTGSR DCSTQTERGT ESNKTAAVAP ISVPAPVAAA ATAAAITATA ATITTTMVAA APVAVAAAAA PAAAAAPSPA TAAATAAAVS PAAAGQIPAA ASVASAAAVA PSAAAAAAVQ VAPAAPAPVP APALVPVPAP AAAQASAPAQ TQAPTSAPAV APTPAPTPTP AVAQAEVPAS PATGPGPHRL SIPSLTCNPD KTDGPVFHSN TLERKTPIQI LGQEPDAEMV EYLI
Explore Angiomotin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets